The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia.
- 3rd ed.
- 1 online resource (312 pages)
Cover -- Title -- Copyright -- Contents -- Acronyms/Abbreviations -- Introduction -- Rationale -- Scope of Document -- Overview of the Development Process -- Rating the Strengths of Guideline Statements and Supporting Research Evidence -- Proper Use of Guidelines -- Guideline Statement Summary -- Guideline Statements and Implementation -- Assessment and Determination of Treatment Plan -- Statement 1: Assessment of Possible Schizophrenia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 2: Use of Quantitative Measures -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 3: Evidence-Based Treatment Planning -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Pharmacotherapy -- Statement 4: Antipsychotic Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 5: Continuing Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 6: Continuing the Same Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement. Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 7: Clozapine in Treatment-Resistant Schizophrenia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 8: Clozapine in Suicide Risk -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 9: Clozapine in Aggressive Behavior -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 10: Long-Acting Injectable Antipsychotic Medications -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 11: Anticholinergic Medications for Acute Dystonia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 12: Treatments for Parkinsonism -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 13: Treatments for Akathisia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement. Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 14: VMAT2 Medications for Tardive Dyskinesia -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Psychosocial Interventions -- Statement 15: Coordinated Specialty Care Programs -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 16: Cognitive-Behavioral Therapy -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 17: Psychoeducation -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 18: Supported Employment Services -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 19: Assertive Community Treatment -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 20: Family Interventions -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations. Quality Measurement Considerations -- Statement 21: Self-Management Skills and Recovery-Focused Interventions -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 22: Cognitive Remediation -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 23: Social Skills Training -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Statement 24: Supportive Psychotherapy -- Implementation -- Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement -- Review of Available Guidelines From Other Organizations -- Quality Measurement Considerations -- Areas for Further Research in Individuals With Schizophrenia -- Guideline Development Process -- Management of Potential Conflicts of Interest -- Guideline Writing Group Composition -- Systematic Review Methodology -- Rating the Strength of Supporting Research Evidence -- Rating the Strength of Guideline Statements -- Use of Guidelines to Enhance Quality of Care -- External Review -- Funding and Approval -- Glossary of Terms -- References -- Disclosures -- Individuals and Organizations That Submitted Comments -- Appendix A. Clinical Questions -- Appendix B. Search Strategies, Study Selection, and Search Results -- AHRQ Review -- Treatment of Neurological Side Effects of Antipsychotic Medications -- Appendix C. Review of Research Evidence Supporting Guideline Statements. Assessment and Determination of Treatment Plan -- Statement 1: Assessment of Possible Schizophrenia -- Statement 2: Use of Quantitative Measures -- Statement 3: Evidence-Based Treatment Planning -- Pharmacotherapy -- Statement 4: Antipsychotic Medications -- Statement 5: Continuing Medications -- Statement 6: Continuing the Same Medications -- Statement 7: Clozapine in Treatment-Resistant Schizophrenia -- Statement 8: Clozapine in Suicide Risk -- Statement 9: Clozapine in Aggressive Behavior -- Statement 10: Long-Acting Injectable Antipsychotic Medications -- Statement 11: Anticholinergic Medications for Acute Dystonia -- Statement 12: Treatments for Parkinsonism -- Statement 13: Treatments for Akathisia -- Statement 14: VMAT2 Medications for Tardive Dyskinesia -- Psychosocial Interventions -- Statement 15: Coordinated Specialty Care Programs -- Statement 16: Cognitive-Behavioral Therapy -- Statement 17: Psychoeducation -- Statement 18: Supported Employment Services -- Statement 19: Assertive Community Treatment -- Statement 20: Family Interventions -- Statement 21: Self-Management Skills and Recovery-Focused Interventions -- Statement 22: Cognitive Remediation -- Statement 23: Social Skills Training -- Statement 24: Supportive Psychotherapy -- Appendix D. Strength of Evidence -- Table D-1. Pharmacological treatment -- Table D-2. Assertive community treatment (ACT) -- Table D-3. Cognitive-behavioral therapy (CBT) -- Table D-4. Cognitive remediation -- Table D-5. Family interventions -- Table D-6. Intensive case management -- Table D-7. Illness management and recovery -- Table D-8. Psychoeducation -- Table D-9. Social skills training -- Table D-10. Supported employment -- Table D-11. Supportive therapy -- Table D-12. Early interventions for patients with first-episode psychosis -- Table D-13. Co-occurring substance use and schizophrenia -- Back Cover.
The guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. The guideline provides direction on implementing these recommendations into clinical practice, with the goal of improving the quality of care and treatment outcomes for patients with schizophrenia.